Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study
Jean-Jacques Kiladjian1, 2, Christoph Klade3, Pencho Georgiev4, et al.
1 Hopital Saint-Louis, Paris, France
2 Centre d'Investigations Cliniques (INSERM CIC 1427), AP-HP, Hopital Saint-Louis, Université de Paris, Paris, France
3 AOP Orphan Pharmaceuticals AG, Vienna, Austria
4 University Multiprofile Hospital for Active Treatment “Sveti Georgi”, and Medical University Plovdiv, Plovdiv, Bulgaria
Program: Oral and Poster Abstracts Type: Oral Session: 634. Myeloproliferative Syndromes: Clinical: Emerging and Novel Targeted Therapies Hematology Disease Topics & Pathways: Therapies, Non-Biological, Clinically Relevant Monday, December 9, 2019: 7:00 AM W304EFGH, Level 3 (Orange County Convention Center) Authors: Jean-Jacques Kiladjian1, 2, Christoph Klade3, Pencho Georgiev4, et al. 1 Hopital...